CANCERS BRONCHIQUES NON A PETITES CELLULES AU STADE AVANCE |
|
|
Référence |
chimiothérapie |
n |
(stIV) |
% RO |
p |
SM |
p |
|
Einhorn, 1986 |
I. CDDP (120 mg/m2) + VDS |
41 |
(36) |
27 |
NS |
26 s. |
NS |
|
II. CDDP(60 mg/m2) + VDS + MMC |
41 |
(35) |
20 |
17 s. |
|||
|
Bonomi, 1989 |
I. CDDP (60 mg/m2) + VBL |
175 |
(175) |
13 |
0,03 |
25 s. |
NS |
|
II. CDDP (40 mg/m2) + VBL + MMC |
176 |
(176) |
20 |
23 s. |
|||
|
Crino, 1990 |
I. CDDP (100 mg/m2) + VP16 |
69 |
(40) |
30 |
NS |
42 s. |
NS |
|
II. Idem + MMC |
57 |
(42) |
26 |
35 s. |
|||
|
Fukuoka, 1991 |
I. CDDP (100 mg/m2) + VDS |
67 |
(30) |
33 |
NS |
50 s. |
NS |
|
II. CDDP (80 mg/m2) + VDS + MMC |
68 |
(28) |
43 |
42 s. |
|||
|
Shinkai, 1991 |
I. CDDP (80 mg/m2) + VDS |
63 |
(43) |
23 |
NS |
9,1 m. |
NS |
|
II. Idem + MMC |
61 |
(37) |
35 |
10,5m. |
|||
|
Weick, 1991 |
I. CDDP (100 mg/m2) + VBL |
142 |
(142) |
24 |
NS |
5,9 m. |
NS |
|
II. Idem + MMC |
134 |
(134) |
17 |
5,0 m. |
|||
|
Mylonakis, 1992 |
I. CDDP(120 mg/m2) + VBL |
52 |
(26) |
29 |
NS |
35 s. |
NS |
|
II. Idem + MMC |
51 |
(27) |
16 |
32 s. |
|||
|
Gandara, 1993 |
I. CDDP (2x50 mg/m2) |
105 |
(105) |
12 |
0,05 |
6,9 m. |
NS |
|
II. CDDP(2x100 mg/m2) |
108 |
(108) |
14 |
5,3 m. |
|||
|
III.Idem II + MMC |
110 |
(110) |
27 |
7,2 m |
|||
|
Gebbia, 2002 |
I. CDDP (100 mg/m²) + VNR |
122 |
(55) |
39 |
NS |
7 m |
NS |
|
II. CDDP (100 mg/m²) + VDS + MMC |
125 |
(58) |
42 |
8 m |
Références
(1) Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR et al. Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 1986; 4(7):1037-1043.
(2) Bonomi PD, Finkelstein DM, Ruckdeschel JC, Blum RH, Green MD, Mason B et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7(11):1602-1613.
(3) Crino L, Tonato M, Darwish S, Meacci ML, Corgna E, Di Costanzo F et al. A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990; 26(1):52-56.
(4) Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K et al. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin [see comments]. J Clin Oncol 1991; 9(4):606-613.
(5) Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A et al. A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1991; 27(5):571-575.
(6) Weick JK, Crowley J, Natale RB, Hom BL, Rivkin S, Coltman CAJ et al. A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1991; 9(7):1157-1162.
(7) Mylonakis N, Tsavaris N, Bacoyiannis C, Karvounis N, Kakolyris S, Karabelis A et al. A randomized prospective study of cisplatin and vinblastine versus cisplatin, vinblastine and mitomycin in advanced non-small cell lung cancer. Ann Oncol 1992; 3(2):127-130.
(8) Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 1993; 11(5):873-878.
(9) Gebbia V, Galetta D, Riccardi F, Gridelli C, Durini E, Borsellino N et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer 2002; 37(2):179-187.